Cancer Clinical Trial
Official title:
Comparison of Aprepitant vs. Gabapentin in the Prevention of Delayed Nausea and Vomiting
1. To compare the effectiveness of gabapentin (titrated to300mg TID days -2 to 5) with
aprepitant (125mg on day 1 and 80mg on days 2 and 3) in the control of delayed nausea
and vomiting associated with level 3, 4 or 5 emetogenic chemotherapy in patients who
experienced delayed nausea and/or vomiting during their first cycle of chemotherapy.
2. To evaluate and compare the safety profile associated with each anti-emetic regimen.
3. To assess subject satisfaction with anti-emetic therapy.
The purpose of study is to compare the effectiveness of aprepitant and gabapentin in
treating "delayed" (days later) nausea and/or vomiting for patients receiving chemotherapy
treatment for cancer. Patients on the study will receive aprepitant or gabapentin in
addition to the standard medications used to prevent nausea and vomiting. Aprepitant is
approved by the FDA for nausea and vomiting. Gabapentin is approved by the FDA for the
treatment of seizures but it may be effective in controlling nausea and vomiting due to
chemotherapy. Subjects receiving aprepitant will be receiving a proven treatment for delayed
nausea and vomiting, while subjects receiving gabapentin will be receiving a drug that has
only shown limited effectiveness.
Patients are eligible for participation in this study because they are going to receive
chemotherapy that may cause nausea or vomiting. If patients have delayed nausea or vomiting
after the first cycle of treatment, they will be offered a chance to receive additional
treatments with their second cycle of chemotherapy. The University of New Mexico Health
Sciences Center is sponsoring the study.
The first 40 patients enrolled in the study will participate in the pilot phase of the
study. A pilot study is a smaller version of a full study to determine how effective the
treatments are. All 40 patients in the pilot phase of the study will come from UNM. If the
pilot phase is found to be successful, then the study will continue and approximately 200
patients will eventually be enrolled. The full study will be conducted at the University of
New Mexico Cancer Research and Treatment Center (UNM CRTC), the New Mexico VA Healthcare
System, and at members of the New Mexico Cancer Care Alliance.
;
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|